US proposes up to 200% tariffs on generic drugs

On July 22, 2026, President Donald Trump proposed tariffs of up to 200% on imported generic medicines, a step that would directly target supply chains tied to Indian manufacturers. Market reaction so far is limited; Reaction pending.

Up to 200% tariff proposal

The proposal would levy steep duties on generic drug imports, a measure the administration says is intended to encourage onshoring of pharmaceutical production. Industry officials said the announcement has heightened uncertainty for contract manufacturers and exporters that rely on the US market.

India's cost advantage and US reliance on imported generics complicate rapid supply shifts. Analysts said production economics favor established Indian sites, and current US dependence on imports means replacement would be costly and slow. Officials pointed to lengthy US facility approval timelines as a practical barrier to immediate reshoring.

Manufacturers and buyers face near-term logistics and contracting questions. Industry officials said companies are reviewing supplier agreements and pricing clauses; hospitals and pharmacies could seek temporary waivers or alternative sourcing if duties are enacted.

Watch whether the administration publishes a formal tariff rule by July 29, 2026; that date will mark when firms must start quantifying duty exposure and adjusting procurement. Until then, commercial and trade negotiators will likely seek clarifications that determine the scale and timing of any disruption.